The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALL

June 21, 2024

Ibrahim Aldoss, MD, City of Hope Comprehensive Cancer Center, Elias Jabbour, MD, MD Anderson Cancer Center

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Related Content:

City of HopeThe University of Texas MD Anderson Cancer CenterHematologic Oncology

An Era of Firsts in CML: Asciminib Challenges SOC TKIs

Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual Patients

Dr Battiwalla on the Utility of Emerging Therapies for Aggressive FL Management